According to the European Medicines Agency (EMA), the key challenges facing the EU's radiopharmaceutical sector include dependency on raw materials, supply issues, and limited production capacity.

Europe is at risk of facing a shortage of radioactive pharmaceutical products unless it addresses its reliance on raw materials from Russia and the United States and improves the efficiency of cross-border transportation. This warning comes from experts at the European Medicines Agency (EMA). They emphasize that simply increasing the production of radiopharmaceuticals will not be enough to ensure adequate supply across Europe.

Radiopharmaceuticals contain radioactive isotopes essential for the diagnosis and treatment of various diseases, primarily malignant tumors, Euronews reports.

The production and transport of radiopharmaceuticals are strictly regulated by laws and standards. The EMA warns that the current supply chain within the EU is not only limited by production capacity but also hampered by transport regulations. The agency is particularly concerned about the EU’s heavy dependence on third countries for critical raw materials.